Sylentis, SA

Sylentis is a biopharmaceutical company founded in 2006 and part of the PharmaMar group (BME: PHM). It describes itself as a pioneer in the development of novel drugs based on RNA interference (RNAi) technology, using artificial intelligence and its proprietary SirFinder™ software to design siRNA compounds. Its most advanced developments are focused on ophthalmology, including dry eye syndrome, macular degeneration and ocular allergies. It also offers siRNA development services and CDMO services.

Sylentis was founded in 2006 and is part of the PharmaMar group (BME: PHM). The company states it is a pioneer in the development of novel drugs based on RNA interference (RNAi) technology, with a mission to build a solid and sustainable business and become a leader in the development of RNAi-based products. It has established an RNAi-based drug discovery platform, SirFinder™, and applies artificial intelligence to drug development. Its most advanced developments are focused on ophthalmology, including dry eye syndrome, macular degeneration and ocular allergies.

Pioneer in RNAi-based drug development, focused on ocular gene silencing and eye health.

• SYL1801

  Chemically modified siRNA engineered using SirFinder™, in Phase II clinical research for wet age-related macular degeneration (AMD), administered as eye drops.

• Tivanisiran (SYL1001)

  Small interfering RNA (siRNA) administered as eye drops, in Phase 3 clinical research for Dry Eye Disease.

1. 1Sylentis – RNAi Biopharmaceuticalssylentis.com
2. 2About Sylentis – Sylentissylentis.com
3. 3Products SYL1801 – Sylentissylentis.com
4. 4Products Tivanisirán – Sylentissylentis.com